Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

dministered, small molecule pharmacological chaperone being developed for the treatment of Pompe disease. In June 2008 Amicus initiated Phase 2 clinical trials of HGT-3510, an orally administered, small molecule pharmacological chaperone being jointly developed for the treatment of Pompe disease by Shire and Amicus. This trial was placed on clinical hold in February 2009 in response to reports of two serious adverse events probably related to treatment with HGT-3510. Shire has rights to HGT-3510 in markets outside the US.

Early Research Products

A number of additional projects are underway in the early stages of development for the HGT business area.

Business Development

As a result of the issues associated with the loss or expiry of patent protection or market exclusivity, Shire seeks to focus its business development activity on the acquisition and in-licensing of products and projects which have the benefit of long-term patent protection and market exclusivity.

The Group remains active in seeking out opportunities to acquire new products or companies that fit its business strategy, its existing therapeutic areas or are in complementary therapeutic areas. During 2008 Shire:

    - acquired more than 98% of Jerini, adding Jerini's HAE product, FIRAZYR,
      to the portfolio; and

    - acquired the global rights to METAZYM, a clinical candidate
      arylsulfatase-A, from Zymenex.

In 2007, the Group acquired New River, allowing Shire to capture the full economic value of VYVANSE and gain control of the development and commercialization of this product. In 2007 Shire also in-licensed the rights to AMIGAL, PLICERA and AT-2220, three pharmacological chaperone compounds for lysosomal storage disorders in markets outside the US; SPD550 for Celiac disease in markets outside of the US and Japan; and worldwide rights (excluding EU member states) to
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) announced today ... serve in a newly created position of Senior Vice ... be responsible for managing the operations of Bio-Techne,s Protein ... in July 2014 and the recently acquired CyVek business. ... ProteinSimple develops and commercializes proprietary systems and consumables that ...
(Date:11/24/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted an additional abbreviated ... Drug Administration (FDA), which brings the Company,s total number ... submissions now pending at the FDA. ... Company, commented, "Our team here at IGI has continued ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... diagnostic tests for cancer and other conditions, today announced that ... at the Science for Business BioWin Day 2014, being held ... The data come from VolitionRx,s lung cancer pilot study, the ... the Centre Hospitalier Universitaire (CHU) de Liege in ...
Breaking Biology Technology:CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3IGI Laboratories, Inc. Announces ANDA Submission 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... , , LONDON and ... Silence Therapeutics plc (AIM: SLN) today announced that Philip Haworth ... update at the 12th Annual BIO CEO & Investor Conference.  The conference ... in New York City . , Silence,s presentation will take place ...
... OAK RIDGE, Tenn., Feb. 4, 2010 -- Four Oak ... that will receive five-year research grants as part of ... The $85 million program, funded under the American ... Science, is designed to support exceptional researchers during the ...
... , Feb. 4 A comprehensive study of ... community oncology practices revealed that Medicare covers only 56% of ... room services to seniors with cancer. The remaining costs -- ... and follow-up care planning -- are not reimbursed by Medicare, ...
Cached Biology Technology:Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 2Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 34 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 2Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 4
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... PORT WASHINGTON, N.Y., Sept. 15, 2011 Sandata ... technology solutions to the home care industry, today ... verification functionality to further support Consumer Directed Services ... authorization support and tracking, an enhanced Plan of ...
... by microbes, infection, or how medical discoveries shape our modern ... book just published by ASM Press, brings to life the ... way we think about and treat infection. Through ... of the germ theory of disease and presents the inside ...
... snails successfully crossed Central America, long considered an impenetrable ... yearsboth times probably by flying across Mexico, stuck to ... and introducing new genes that contribute to the marine ... airplanes to fly overseas, marine snails may use birds ...
Cached Biology News:Enhanced Santrax Electronic Visit Verification Functionality for Consumer Directed Services Programs 2Enhanced Santrax Electronic Visit Verification Functionality for Consumer Directed Services Programs 3The remarkable history of medicine's battle with infectious diseases 2Hitchhiking snails fly from ocean to ocean 2Hitchhiking snails fly from ocean to ocean 3
... Nonreversible lids with condensation ... Individual alphanumerical codes for ... for ease in stacking,• ... attachment,• Sterilized by gamma ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Biology Products: